Associated Papers
Inhibition of FLT3-induced signalling in refractory acute myeloid leukaemia.
Yang J et al.
Bioorganic Chemistry, 2025
Structural modifications and kinetic effects of KRAS interactions with HRAS and NRAS: an in silico comparative analysis of KRAS mutants.
Silverman I et al.
Frontiers in Molecular Biosciences, 2024
Mutational landscape of K-Ras substitutions at 12th position-a systematic molecular dynamics approach.
S UK et al.
Journal of Biomolecular Structure & Dynamics, 2022
A H-REV107 Peptide Inhibits Tumor Growth and Interacts Directly with Oncogenic KRAS Mutants.
Han CW et al.
Cancers, 2020
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H et al.
Ebiomedicine, 2019
Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway.
Sakakibara K et al.
International Journal of Hematology, 2019
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.
Hayama T et al.
International Journal of Colorectal Disease, 2019
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.
Lu S et al.
Chemical Society Reviews, 2016
Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.
Tong JH et al.
Cancer Biology & Therapy, 2014
Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Schultz NA et al.
Pancreas, 2012
Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells.
Somwar R et al.
Journal of Biomolecular Screening, 2009
High BRAF mutation frequency does not characterize all melanocytic tumor types.
Saldanha G et al.
International Journal of Cancer, 2004
Select a paper to view details